Interpace Biosciences, Inc. (IDXG)

1.4100 +0.0500 (+3.68%) 收市：12:07PM EDT

Interpace Biosciences, Inc.

Waterview Plaza
Suite 310 2001 Route 46
Parsippany, NJ 07054
United States
855 776 6419
https://www.interpace.com

版塊: Healthcare
行業: Diagnostics & Research
全職員工: 108

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Thomas W. Burnell Ph.D.	President, CEO & Chairman	678.41k	無	1963
Mr. Christopher McCarthy	Chief Financial Officer	307.04k	無	1992
Dr. Sydney D. Finkelstein	Chief Scientific Officer	無	無	無
Mr. Jody Campbell	Chief Revenue Officer	無	無	無
Dr. Nicole Massoll M.D.	Chief Medical Officer	無	無	無
Mr. Patrick Kane	VP & Corporate Controller	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company primarily serves physicians, cancer center, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

公司管治

截至 無 止，Interpace Biosciences, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。